Veracyte, Inc.VCYT

Veracyte’s most recent SEC filings show the company booked $139.1 million of revenue in the quarter to 31 March 2026, up from the prior quarter, while net income came in at $28.7 million and diluted EPS settled at $0.35 on 81.3 million shares. Operating income of $22.6 million and $35.2 million of operating cash flow tell a story of modest profitability, but the balance sheet still carries only $263.1 million of cash and equivalents against $92.0 million of liabilities, leaving shareholders’ equity at $1.34 billion.

The company sells a portfolio of molecular cancer tests and is building an AI-driven whole-genome monitoring platform called TrueMRD, with management flagging a bladder-cancer MRD test launch “expected in 2026.” The firm also highlights ongoing clinical collaborations and a pipeline of “market-leading molecular tests,” but none of these product pages contain revenue lines-only promises, images, and clinical-study summaries.

On the hard numbers front, the same 10-Q shows $27.1 million of R&D spend in the quarter, $3.0 million of capex, and inventory of $20.5 million at 31 December 2025 (up $2.9 million year-over-year), while short-term investments reported at year-end 2025 totalled $50.3 million. The 10-Q and 10-K do not include product-level revenue splits, segment margins, or cash flow statements beyond operating and capex totals, so the source requires readers to infer working-capital and inventory turns from the single inventory line and the cash roll-forward.

For a look at the daily chart context, the official source rail does not supply a TradingView route, so readers are directed to their own charting platform using the ticker VCYT on Nasdaq; the company’s investor-relations site lists the primary listing as Nasdaq Global Select Market with no dual listings or regional exchange references.

What changed recently: six insider Form 4 filings in late June, a 144 filing on 18 June, and routine periodic reports ending 22 June. Nothing in the evidence set signals a new product launch, regulatory approval, or material contract win; the clinical-study pages confirm ongoing validation rather than commercial milestones. Accordingly, the file’s tension is the gap between the platform narrative-whole-genome MRD, AI-driven precision oncology-and the disclosed financial footprint, which is still dominated by a single revenue line, modest cash generation, and a share count that keeps creeping up.